{
  "id": 6317527,
  "title": "Breast Cancer Drug Wins Approval Despite Rejection by Agency Advisors",
  "url": "https://urgent.news/2026/09/08/breast-cancer-drug-wins-approval-despite-rejection-by-agency-advisors",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-08T18:16:23.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/hematologyoncology/breastcancer/122920"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- The FDA on Friday granted accelerated approval to camizestrant (Etcamah) for treating hormone receptor-positive/HER2-negative breast cancer at the first sign of ESR1 resistance mutations during first-line treatment. Camizestrant...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}